Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
First healthy volunteers dosed in Bionyra’s Phase I BYN-001 study
Bionyra Pharma has dosed the first healthy volunteers in a Phase I trial of BYN-001, its long-acting anti-IL-25 monoclonal antibody, which …
-
J&J’s new reusable contact lens secures CE Mark
Johnson & Johnson (J&J) has received the CE Mark for its ACUVUE OASYS MAX 2-Week, a new reusable contact lens …
-
ABEC to expand global manufacturing network with new Wilson facility
ABEC is set to open a new manufacturing facility in Wilson, North Carolina, US, expanding its network for biopharmaceutical process …
-
FDA grants 510(k) clearance to Emboliner system for TAVR procedures
Emboline has secured 510(k) clearance from the US Food and Drug Administration (FDA) for its Emboliner embolic protection system, intended …
-
Tyra announces initial data from Phase II SURF302 trial of dabogratinib
Tyra Biosciences has reported initial data from its Phase II SURF302 clinical trial of the oral drug dabogratinib in FGFR3-altered …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
TwoStep Therapeutics has raised $62.5m in an oversubscribed Series A financing round to support its lead peptide-drug conjugate, TS-104, for …
-
Labcorp acquires MLM Medical Labs to expand global central lab network
Labcorp has acquired MLM Medical Labs, expanding its worldwide central laboratory and biomarker capabilities for clinical studies. MLM is a central …
-
BMS reports positive data from Phase II QUINTESSENTIAL study for r/r MM
Bristol Myers Squibb (BMS) has reported positive top-line results from the registrational Phase II QUINTESSENTIAL trial of arlocabtagene autoleucel (arlo-cel; …
-
FDA grants RMAT designation to RiboX’s RXRG001 for xerostomia
The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to RiboX Therapeutics’ investigational treatment …
-
Nyxoah implants first patient in BREATHE study of Genio
Belgium-based medical technology company Nyxoah has implanted the first patient in BREATHE, its US post-approval study of the Genio system …
-
Rezubio doses first cohort in Phase I trial of inhaled RZ-520
Rezubio has dosed the first cohort of patients in a Phase I trial of RZ-520, an inhaled therapeutic drug for …
-
Novartis India acquires Pfizer brands for $132m
Novartis India has agreed to pay Rs12.5bn ($132m) to acquire the Minipres and Minipress trademarks in India, along with certain …
-
Philips launches eV14-2v transvaginal transducer
Philips has introduced the eV14-2v transvaginal transducer, an addition to its ultrasound range for obstetrics and gynaecology. The device has received …
-
Novartis’ pelacarsen fails to meet primary endpoint in Lp(a)HORIZON trial
Novartis has reported that the Phase III Lp(a)HORIZON trial of pelacarsen failed to meet its primary endpoint in patients with …
-
FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer
The US Food and Drug Administration (FDA) has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a cyclin-dependent kinase …
